Pharmaceutical packaging failures: The real cost of recalls, rejections and non-compliance

The costs go beyond replacing packaging. Failures can mean product write-offs, stock retrieval, remanufacturing and regulatory scrutiny, while damaging trust with distributors, pharmacies and customers.

Not every failure leads to a recall. Non-compliance can be caught earlier at QA/QC, during customs clearance or before a product reaches the shelf, resulting in delays and wasted production runs.

In this article, we’ll explore what pharmaceutical packaging failures look like, what they really cost, where non-compliance can creep in, and how businesses can reduce the risk before products leave the facility.

What actually counts as a packaging failure

Pharmaceutical packaging failures aren’t limited to damaged boxes or broken containers. They can occur at several points across the packaging and supply chain, including:

• Physical failures: Broken seals, damaged tamper-evident features, or packaging that doesn’t withstand handling and transit.
• Regulatory failures: Incomplete or incorrect labelling, missing unique identifiers or serialisation, and non-compliant child-resistant closures.
• Supply chain failures: Temperature excursions during transit, contamination risks, or weak points in packaging that could make products vulnerable to counterfeiting.

Any of these issues can delay a batch, trigger rejection or, in more serious cases, contribute to a product recall.

The real cost of a recall

A pharmaceutical recall can quickly become a significant financial and operational burden. The costs typically fall into three areas:

• Direct costs: Writing off affected products, retrieving stock from the supply chain and remanufacturing replacement batches.
• Regulatory fallout: Meeting MHRA reporting obligations, implementing corrective action plans and managing follow-up inspections or investigations.
• Commercial damage: Losing trust with distributors and pharmacies, putting contracts at risk and facing reputational damage that can last long after the recall is resolved.

The true cost of a recall, therefore, extends far beyond the value of the products being withdrawn.

The cost of rejection before a product even reaches shelf

Not every pharmaceutical packaging failure results in a recall. Many issues are identified during quality checks, at customs or before a batch is released, but these early-stage failures can still create significant costs, delays and disruption.

• QA/QC rejections: Pharmaceutical packaging defects such as poor seals, incorrect components or damaged packaging can cause batches to fail quality checks and delay product release. In some cases, the packaging may need to be replaced, or the batch reworked before it can proceed.
• Customs and import delays: Non-compliant or incorrect labelling can result in products being held at customs, particularly when requirements differ between markets. Delays can disrupt distribution schedules and increase storage and handling costs.
• Wasted production runs: If packaging doesn’t match the approved specification, an otherwise compliant product may not be releasable. This can mean scrapping packaging materials, reworking finished products or repeating part of the production process.

These failures may happen before a product ever reaches the shelf, but the financial impact can still be substantial. Getting pharmaceutical packaging right from the outset helps avoid unnecessary waste and keeps production and distribution moving.

Where non-compliance usually creeps in

Pharmaceutical packaging compliance covers more than simply getting the box or label right. Requirements can apply across security, labelling, child resistance and even the materials used.

Falsified Medicines requirements

Anti-tampering features and unique identifiers or serialisation are key requirements for protecting products and helping verify their authenticity throughout the supply chain.

MHRA labelling requirements

Labelling and patient information leaflets must contain the correct information and meet regulatory requirements. Errors, outdated artwork or incorrect market-specific information can all create compliance issues.

Child-resistant packaging

Where required, packaging must meet relevant standards such as ISO 8317, demonstrating that it provides an appropriate level of resistance to opening by children while remaining accessible to intended users.

Evolving packaging obligations

Compliance doesn’t stand still. Requirements such as Extended Producer Responsibility (EPR) and packaging material reporting are adding further obligations for pharmaceutical businesses to consider when selecting and managing packaging.

The root causes behind most failures

Many pharmaceutical packaging failures start long before a product reaches production. When packaging is treated as an afterthought, important compliance and performance requirements can be missed or addressed too late in the development process.

The use of generic, non-validated materials instead of pharma-grade packaging can also introduce unnecessary risks, while poor version control can lead to outdated or incorrect artwork and labelling being used across different markets.

Testing is another common weak point. Skipping or rushing checks such as drop testing, temperature cycling and seal integrity testing can leave packaging vulnerabilities undiscovered until products are already in the supply chain.

How to reduce the risk

Reducing pharmaceutical packaging risk starts with addressing compliance and performance requirements from the beginning, rather than after manufacturing sign-off. A few practical steps can make a significant difference:

• Design for compliance from day one: Build MHRA and FMD requirements into packaging design, specifications and material selection from the outset.
• Test for real-world conditions: Test packaging against transit, handling and storage conditions, including seal integrity, temperature cycling and drop testing.
• Keep documentation audit-ready: Maintain accurate validation records, specifications and artwork versions so compliance can be demonstrated quickly when required.

Working with a packaging partner that understands pharmaceutical requirements can help bring all of these elements together and reduce the risk of costly failures.

How Swiftpak helps pharma businesses avoid these costs

Pharmaceutical packaging is too important to leave until the final stage of product development. The right packaging can help protect products, meet regulatory requirements and reduce the risk of costly rejections, delays and recalls.

At Swiftpak, we understand the demands of pharmaceutical packaging and the importance of getting it right from the start. From material selection and packaging design to testing and compliance, our team can help you develop packaging that is fit for purpose and built around the requirements of your product and market.

Don’t wait for a packaging failure to expose a weakness in your process. Talk to the Swiftpak team about compliant, tested pharmaceutical packaging before it becomes a recall.